Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
Globe Newswire•04/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.